Dingdang Health rises over 5% as company expands into weight loss market and advances collaboration with innovative drug enterprises

According to the Zhicheng Finance APP, Dingdang Health (09886) rose more than 5%. As of press time, it surged 6.82% to HK$0.94, with a turnover of HK$5.2407 million.

On the news front, recently, Dingdang Health announced a cooperation with Wilex Group. Following the Beijing area, Dingdang Health officially listed tirzepatide injection (Mounjaro) in its pharmacies in Guangzhou and Shenzhen. According to a research report by TF Securities, in 2020, more than 2.6 billion people worldwide were affected by overweight/obesity, and the weight loss market continues to expand. Eli Lilly is one of the leading enterprises in the weight loss field.

Dingdang Health stated that, relying on Lilly's excellent innovative drug products and professional health education capabilities, as well as Dingdang Health’s extensive multifunctional smart pharmacy network, end-to-end intelligent warehousing and distribution system, professional team of doctors and pharmacists, and full lifecycle health management system, both parties will jointly provide one-stop health solutions for people with overweight/obesity, diabetes, etc., enhancing the accessibility of medications and the level of health management.